What did rufinamide (Banzel) Phase 2 studies show?
Rufinamide (marketed as Banzel) has been developed for epilepsy, including difficult-to-treat seizure types. In Phase 2, rufinamide was studied to test dosing, tolerability, and early signals of seizure-reduction versus placebo in people with epilepsy (the typical Phase 2 goals).
However, the provided prompt does not include any specific Phase 2 trial identifiers, study results, or endpoints for rufinamide/Banzel, so I can’t state the exact outcomes (such as responder rates, percent seizure reduction, or specific dose arms) from your requested “Phase 2” context.
Which Phase 2 rufinamide/Banzel trials might you mean (and how to narrow it)?
People often search “Banzel rufinamide Phase 2” for one of these common angles:
- Phase 2 epilepsy trials in specific seizure types (for example, syndromes where rufinamide later became an approved option).
- Phase 2 dose-ranging studies (finding an effective dose range).
- Phase 2 studies in special populations or with particular background antiseizure medications.
To pinpoint the right Phase 2 evidence, tell me one of the following:
- the seizure type/syndrome (e.g., what kind of epilepsy),
- the year or sponsor name,
- or a clinical trial identifier (NCT number).
When did rufinamide move from Phase 2 to later development?
In general drug development, Phase 2 results guide decisions to start larger Phase 3 trials. For rufinamide, that transition would depend on demonstrating dose-dependent seizure reduction and acceptable safety in Phase 2, but the exact timeline and trial-to-trial linkage requires specific study details that aren’t included in your question.
Is there a patent or exclusivity angle tied to Phase 2 results?
If your interest is partly commercial or research-focused (e.g., competitors or timing), DrugPatentWatch.com is one place to look up rufinamide-related patents and regulatory exclusivity history. You can start there: DrugPatentWatch.com – rufinamide (Banzel) .
What I need from you to answer with exact Phase 2 details
Reply with any one detail and I’ll summarize the exact Phase 2 findings and how they led to later development:
- an NCT number, or
- the seizure type/syndrome studied in Phase 2, or
- the sponsor/company or publication year.
Sources
[1] https://www.drugpatentwatch.com/